{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:40:37Z","timestamp":1760838037405,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21402222"],"award-info":[{"award-number":["21402222"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bmc.2018.10.019","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T02:59:50Z","timestamp":1540177190000},"page":"5780-5791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles"],"prefix":"10.1016","volume":"26","author":[{"given":"Bin","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingya","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2018.10.019_b0005","unstructured":"IDF diabetes atlas-8th edition. http:\/\/www.diabetesatlas.org\/#."},{"key":"10.1016\/j.bmc.2018.10.019_b0010","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.bmc.2018.10.019_b0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14740338.2013.752813","article-title":"A review of the efficacy and safety of oral antidiabetic drugs","volume":"12","author":"Stein","year":"2013","journal-title":"Expert Opin Drug Safety"},{"key":"10.1016\/j.bmc.2018.10.019_b0020","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1517\/17460441.2014.941352","article-title":"Novel approaches to drug discovery for the treatment of type 2 diabetes","volume":"9","author":"Xu","year":"2014","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmc.2018.10.019_b0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(11)60207-9","article-title":"Management of type 2 diabetes: new and future developments in treatment","volume":"378","author":"Tahrani","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.bmc.2018.10.019_b0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic \u03b2 cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2018.10.019_b0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.108.00802","article-title":"International Union of Pharmacology. LXXI. Free Fatty Acid Receptors FFA1, -2, and -3: Pharmacology and Pathophysiological Functions","volume":"60","author":"Stoddart","year":"2008","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmc.2018.10.019_b0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/13543770802665717","article-title":"Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40\/FFA1\/FFAR1): an emerging target for type 2 diabetes","volume":"19","author":"Bharate","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmc.2018.10.019_b0045","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.bmcl.2014.05.019","article-title":"Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus","volume":"24","author":"Defossa","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.10.019_b0050","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13543784.2016.1189530","article-title":"Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development","volume":"25","author":"Li","year":"2016","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2018.10.019_b0055","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1021\/jm300170m","article-title":"Optimization of (2,3-Dihydro-1-benzofuran-3-yl)acetic Acids: Discovery of a Non-Free Fatty Acid-Like, Highly Bioavailable G Protein-Coupled Receptor 40\/Free Fatty Acid Receptor 1 Agonist as a Glucose-Dependent Insulinotropic Agent","volume":"55","author":"Negoro","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.10.019_b0060","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(11)61879-5","article-title":"TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"379","author":"Burant","year":"2012","journal-title":"The Lancet"},{"issue":"2014","key":"10.1016\/j.bmc.2018.10.019_b0065","first-page":"1703","article-title":"Discontinued in 2013: diabetic drugs","volume":"23","author":"Hedrington","year":"2013","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2018.10.019_b0070","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2018.10.019_b0075","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.115.064121","article-title":"Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-induced Liver Injury","author":"Li","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmc.2018.10.019_b0080","first-page":"50","article-title":"Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury","volume":"157","author":"Wolenski","year":"2017","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.bmc.2018.10.019_b0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1021\/ml100106c","article-title":"Structure\u2212Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469","volume":"1","author":"Christiansen","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.10.019_b0090","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1021\/jm101405t","article-title":"Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists","volume":"54","author":"Sasaki","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.10.019_b0095","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.bmcl.2011.10.118","article-title":"AMG 837: A potent, orally bioavailable GPR40 agonist","volume":"22","author":"Houze","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.10.019_b0100","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/ml300133f","article-title":"Discovery of AM-1638: A Potent and Orally Bioavailable GPR40\/FFA1 Full Agonist","volume":"3","author":"Brown","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.10.019_b0105","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1021\/jm2012968","article-title":"Identification of Fused-Ring Alkanoic Acids with Improved Pharmacokinetic Profiles that Act as G Protein-Coupled Receptor 40\/Free Fatty Acid Receptor 1 Agonists","volume":"55","author":"Negoro","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.10.019_b0110","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1016\/j.bmcl.2018.07.048","article-title":"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings","volume":"28","author":"Sun","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.10.019_b0115","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1021\/acs.jmedchem.6b01357","article-title":"Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold","volume":"60","author":"Li","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.10.019_b0120","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/j.bmc.2018.07.050","article-title":"Nitric oxide donor-based FFA1 agonists: design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents","volume":"26","author":"Li","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2018.10.019_b0125","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bmc.2017.12.030","article-title":"Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold","volume":"26","author":"Li","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2018.10.019_b0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1021\/ml500391n","article-title":"Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist","volume":"6","author":"Takano","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.10.019_b0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-pharmtox-010510-100514","article-title":"Bioactivation of Drugs: Risk and Drug Design","volume":"51","author":"Walsh","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bmc.2018.10.019_b0140","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1016\/j.bmcl.2014.04.065","article-title":"Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists","volume":"24","author":"Takano","year":"2014","journal-title":"Bioorganic Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.10.019_b0145","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1016\/j.bmc.2015.07.028","article-title":"Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558","volume":"23","author":"Takano","year":"2015","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/j.bmc.2018.10.019_b0150","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular Properties That Influence the Oral Bioavailability of Drug Candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.10.019_b0155","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1021\/jm2016123","article-title":"Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes","volume":"55","author":"Mikami","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2018.10.019_b0160","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/ml400501x","article-title":"Optimization of GPR40 agonists for type 2 diabetes","volume":"5","author":"Liu","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.10.019_b0165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bmcl.2015.11.050","article-title":"Discovery of the imidazole-derived GPR40 agonist AM-3189","volume":"26","author":"Ma","year":"2016","journal-title":"Bioorganic Med Chem Lett"},{"key":"10.1016\/j.bmc.2018.10.019_b0170","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1021\/jm301470a","article-title":"Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability","volume":"56","author":"Christiansen","year":"2013","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618314573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618314573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:58:17Z","timestamp":1760835497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089618314573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":34,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0968089618314573"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2018.10.019","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2018.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}